Literature DB >> 23901049

The intrarenal renin-angiotensin system: does it exist? Implications from a recent study in renal angiotensin-converting enzyme knockout mice.

Xifeng Lu1, Lodi C W Roksnoer, Alexander H Jan Danser.   

Abstract

A large body of evidence supports the presence of local production of angiotensins in the kidney. It is widely believed that renin-angiotensin system (RAS) blockers, through interference with such production and/or the local effects of angiotensin (Ang) II, exert protective renal effects. Yet, whether such production affects blood pressure independently from the circulating RAS is still a matter of debate. To investigate this, a recent study by Gonzalez-Villalobos et al. (J Clin Invest 2013; 123: 2011-2023) has studied the consequences of infusing Ang II or the nitric oxide synthase inhibitor l-NAME in mice lacking renal angiotensin-converting enzyme (ACE). They observed blunted blood pressure and renal responses in the renal ACE knockout mice versus wild-type controls. This review discusses to what degree these findings can be considered as unequivocal evidence for ACE-mediated Ang II formation in the kidney as an independent determinant of hypertension.

Entities:  

Keywords:  ACE inhibitor; angiotensin; chymase; diabetes; hypertension; renin

Mesh:

Substances:

Year:  2013        PMID: 23901049     DOI: 10.1093/ndt/gft333

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

Review 1.  Distal convoluted tubule.

Authors:  James A McCormick; David H Ellison
Journal:  Compr Physiol       Date:  2015-01       Impact factor: 9.090

Review 2.  Urinary biomarkers for early diabetic nephropathy: beyond albuminuria.

Authors:  So-Young Lee; Mary E Choi
Journal:  Pediatr Nephrol       Date:  2014-07-25       Impact factor: 3.714

Review 3.  Autophagy in diabetic nephropathy.

Authors:  Yan Ding; Mary E Choi
Journal:  J Endocrinol       Date:  2014-10-27       Impact factor: 4.286

4.  No Brain Renin-Angiotensin System: Déjà vu All Over Again?

Authors:  Curt D Sigmund; Debra I Diz; Mark C Chappell
Journal:  Hypertension       Date:  2017-04-10       Impact factor: 10.190

5.  Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis.

Authors:  Ahmed Alhusban; Ahmad Al-Azayzih; Anna Goc; Fei Gao; Susan C Fagan; Payaningal R Somanath
Journal:  J Pharmacol Exp Ther       Date:  2014-07-02       Impact factor: 4.030

6.  Variation in genes that regulate blood pressure are associated with glomerular filtration rate in Chinese.

Authors:  May E Montasser; Lawrence C Shimmin; Dongfeng Gu; Jing Chen; Charles Gu; Tanika N Kelly; Cashell E Jaquish; Treva K Rice; Dabeeru C Rao; Jie Cao; Jichun Chen; Paul K Whelton; Lotuce Lee Hamm; Jiang He; James E Hixson
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

Review 7.  New frontiers in the intrarenal Renin-Angiotensin system: a critical review of classical and new paradigms.

Authors:  Jia L Zhuo; Fernanda M Ferrao; Yun Zheng; Xiao C Li
Journal:  Front Endocrinol (Lausanne)       Date:  2013-11-11       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.